SciSparc Announces Successful Final Phase IIa Results, Meeting End Points of its Phase IIa Alzheimer Disease Patients with Agitation Trial
Topline results using the Company’s SCI-110 met the trial’s primary and secondary end points, demonstrating…
Topline results using the Company’s SCI-110 met the trial’s primary and secondary end points, demonstrating…
Topline results using the Company’s SCI-110 met the trial’s primary and secondary end points, demonstrating…
CALGARY, Alberta, June 02, 2023 (GLOBE NEWSWIRE) — Providence Therapeutics Holdings Inc. (“Providence”), a biopharmaceutical…
CALGARY, Alberta, June 02, 2023 (GLOBE NEWSWIRE) — Providence Therapeutics Holdings Inc. (“Providence”), a biopharmaceutical…
XI’AN, China, June 02, 2023 (GLOBE NEWSWIRE) — Bon Natural Life Limited (Nasdaq: BON) (“BON”…
XI’AN, China, June 02, 2023 (GLOBE NEWSWIRE) — Bon Natural Life Limited (Nasdaq: BON) (“BON”…
BUFFALO, N.Y., June 02, 2023 (GLOBE NEWSWIRE) — 22nd Century Group, Inc. (Nasdaq: XXII), a…
BUFFALO, N.Y., June 02, 2023 (GLOBE NEWSWIRE) — 22nd Century Group, Inc. (Nasdaq: XXII), a…
HAMPTON, N.J., June 02, 2023 (GLOBE NEWSWIRE) — Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that…
HAMPTON, N.J., June 02, 2023 (GLOBE NEWSWIRE) — Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that…
Kisqali is the first and only CDK4/6 inhibitor to demonstrate a consistent, clinically meaningful benefit…
Kisqali is the first and only CDK4/6 inhibitor to demonstrate a consistent, clinically meaningful benefit…
CAMBRIDGE, Mass. and NEW YORK, June 02, 2023 (GLOBE NEWSWIRE) — Black Diamond Therapeutics, Inc….
CAMBRIDGE, Mass. and NEW YORK, June 02, 2023 (GLOBE NEWSWIRE) — Black Diamond Therapeutics, Inc….
LONDON, June 02, 2023 (GLOBE NEWSWIRE) — Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced that its…
LONDON, June 02, 2023 (GLOBE NEWSWIRE) — Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced that its…
ARLINGTON, Mass., June 02, 2023 (GLOBE NEWSWIRE) — Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical…
ARLINGTON, Mass., June 02, 2023 (GLOBE NEWSWIRE) — Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical…
IRVINE, Calif., June 02, 2023 (GLOBE NEWSWIRE) — Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today…
NEW YORK–(BUSINESS WIRE)–Massive Bio, a leading artificial intelligence (AI) analytics company specializing in precision oncology,…